ChinaPeptides: difference between revisions
Diff·revision 14 → 15·06:44, 17 Mar 2025
Difference between revision 14 and revision 15 of ChinaPeptides. 3 lines changed; the page grew by 274 bytes.
| Revision 14 — 13:23, 1 Mar 2025 IncretinIvo (talk) correct the trading name — the short code and the legal name are different things 7,013 bytes +144 | Revision 15 — 06:44, 17 Mar 2025 TallySheetTad (talk) expand §Regulatory position and legal status 7,287 bytes +274 | ||
|---|---|---|---|
| 49 | A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.{{r|usp1503}} | 49 | A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.{{r|usp1503}} |
| 50 | 50 | ||
| + | 51 | == Independent testing record == | |
| + | 52 | Submitted reports on QYB material to July 2026 divide roughly evenly between stock and custom items. For custom items, several purchasers ran independent mass confirmation and reported agreement with the supplier's own figure.{{r|reports}} | |
| + | 53 | ||
| 51 | == References == | 54 | == References == |
| 52 | {{reflist}} | 55 | {{reflist}} |